Aug 12, 2024 8:00am EDT LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
Aug 07, 2024 4:01pm EDT LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
May 08, 2024 4:01pm EDT LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 01, 2024 4:01pm EDT LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Apr 03, 2024 7:00am EDT LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials